Introduction
============

Severe asthma occurs in \~10% of the over 315 million people worldwide affected by the disease.[@b1-jaa-11-063],[@b2-jaa-11-063] Despite treatment with high-dosage inhaled corticosteroids (ICS) plus long-acting β~2~-agonists (LABA), severe asthma often remains uncontrolled placing patients at risk of severe exacerbations.[@b3-jaa-11-063] Eosinophilia is associated with asthma severity, increased exacerbation frequency, impaired lung function, and poor asthma control.[@b4-jaa-11-063]--[@b6-jaa-11-063] Benralizumab (FASENRA^™^), a humanized, afucosylated, anti-interleukin (IL)-5 receptor α monoclonal antibody, is indicated in the USA and the EU for add-on maintenance treatment of patients with severe eosinophilic asthma.[@b7-jaa-11-063] During Phase III trials, subcutaneous benralizumab 30 mg was well tolerated and significantly reduced annual asthma exacerbation rates and oral corticosteroid use, and improved lung function and disease-specific patient-reported outcomes for patients with blood eosinophil counts ≥150 cells/µL.[@b8-jaa-11-063]--[@b11-jaa-11-063]

Patients prefer at-home administration of subcutaneously injected biologics across a variety of therapeutic areas.[@b12-jaa-11-063],[@b13-jaa-11-063] In part to meet this demand, pre-filled syringes, which have become the delivery system of choice for parenteral administration of biologics, are often accessorized to reduce needle stick injury (e.g., with needle guards) and improve usability (e.g., with enlarged finger flanges).[@b14-jaa-11-063],[@b15-jaa-11-063] None of the biologics approved for the treatment of severe asthma are approved for at-home use. As an approach to addressing this unmet need, we assessed the functionality, reliability, and performance of an accessorized pre-filled syringe (APFS) used to administer a fixed dose of benralizumab subcutaneously in a health care setting and at home. Some of the results of this study have been previously reported in the form of an abstract.[@b16-jaa-11-063]

Materials and methods
=====================

Study design and study population
---------------------------------

GREGALE (NCT02417961; pronounced "grey-gah-ley") was a multicenter, nonrandomized, open-label Phase III trial in the USA and Canada. Patients were screened at 26 centers and received treatment at 24 centers. The study included a 2-week screening period, a site administration treatment period (Weeks 0--8), a home administration treatment period (Weeks 12--16), an end-of-treatment visit (Week 20), and a follow-up visit (Week 28; [Figure 1A](#f1-jaa-11-063){ref-type="fig"}).

Male and female patients with severe, uncontrolled asthma qualified for the study if they were 18--75 years old and had a body weight of ≥40 kg. Evidence of asthma was defined as one of the following: airway reversibility based on forced expiratory volume in 1 second (FEV~1~) \>12% and \>200 mL at screening or the first treatment visit or in the previous year prior to study entry; airflow variability in FEV~1~ \>20% between pulmonary function testing in the previous year prior to the first treatment visit; or airflow variability based on \>20% diurnal variability in peak flow. Patients were required also to have a documented history of current treatment with ICS and LABA, morning prebronchodilator FEV~1~ of \>50% predicted at screening or the first treatment visit, and asthma that was documented as not well controlled. Asthma was viewed as not well controlled if the Asthma Control Questionnaire 6 (ACQ-6) score was ≥1.5, the peak flow was 60%--80% of predicted, or ≥1 exacerbation requiring oral or systemic corticosteroids occurred in the previous year. When the ACQ-6 score was \<1.5, asthma was deemed not well controlled if asthma symptoms occurred \>2 days/week, nighttime awakenings occurred ≥1 time/week, or short-acting β~2~-agonists (SABA) were used \>2 days/week, in the 2--4 weeks prior to study entry. Exclusion criteria included clinically important pulmonary diseases other than asthma; a medical disorder that in the opinion of the investigator was not stable and could affect patient safety, study results, or patient completion of trial; and a smoking history of ≥10 pack-years or status as a current smoker. An assessment of whether a disorder would affect a patient or caregiver's ability to administer benralizumab was performed during the supervised on-site training in APFS use.

An independent ethics committee or institutional review board for each study center approved the final study protocol. The approving committees and boards were the Copernicus Group (Durham, NC, USA), the Institutional Review Board Services (Ontario, OTT, Canada), the Hospital Sacre Coeur Comité d'éthique de la recherche (Montreal, QC, Canada), the University of British Columbia Clinical Research Ethics Board (Vancouver, BC, Canada), and the University of Calgary Conjoint Health Research Ethics Board (Calgary, AB, Canada). All patients provided a signed informed consent form prior to study initiation. This study was performed in accordance with the Declaration of Helsinki, the International Council for Harmonisation/Good Clinical Practice guidelines, the applicable regulatory requirements, and AstraZeneca policy on bioethics.

Procedures
----------

Benralizumab (manufactured by AstraZeneca, Gaithersburg, MD, USA) was administered as a 30 mg/mL solution in a 1 mL APFS (Becton Dickinson syringes and accessories were filled, assembled, and packaged by Cook Pharmica LLC, Blooming-ton, IN, USA; [Figure 1B](#f1-jaa-11-063){ref-type="fig"}). Patients received benralizumab on study site visits at Weeks 0, 4, and 8. At Week 0, benralizumab was administered by the principal investigator. At Week 4, the patient/caregiver was given the option of self-administering benralizumab under the supervision of the principal investigator; and at Week 8, the patient/caregiver performed the injection. At Weeks 12 and 16, the patient/caregiver administered benralizumab at home. For home administration, the patient received the APFS instructions for reference. After each home administration, the patients returned for an on-site visit within 48 hours. Patients filled out a questionnaire to indicate whether the syringe functioned properly and whether the dose was administered successfully with each home administration. Both the questionnaire and the used syringe were returned to the study site after each home administration. The study site returned the APFS used for home administration to the study sponsor for *in vitro* evaluation of functionality.

Outcomes
--------

The primary objective was to assess functionality, reliability, and performance of the APFS used to administer benralizumab in the clinic and at home. The primary endpoints were the percentage of dispensed APFS that were used successfully in the clinic and at home, the percentage of malfunctioning APFS at home or in the clinic, and the percentage of returned APFS used to administer at home evaluated as functional. Secondary endpoints assessed benralizumab pharmacokinetics, pharmacodynamics (i.e., eosinophil counts), efficacy (i.e., the change in mean ACQ-6 score from baseline), immunogenicity, and safety. Mild, moderate, and severe adverse events (AEs) were recorded throughout the study. Serious AEs, as defined by the US Food and Drug Administration, were recorded, and the likelihood that a serious AE was or was not related to benralizumab treatment was adjudicated by the principal investigator at each study site.

Successful benralizumab administration with the APFS was defined as a completed injection, a "Yes" answer to all questionnaire inquiries, and a satisfactory result in the in-vitro examination of the device post use. Evaluation of returned APFS for function was based on questionnaire responses, visual inspection, and functional testing. Serum benralizumab concentration and the presence of serum anti-drug antibodies (ADA) were measured predose at Weeks 0 and 8 and at Weeks 20 and 28 with validated bioanalytical methods. Blood eosinophil counts were measured as part of the routine hematology assessments performed at Weeks 0, 20, and 28.

The ACQ-6 is a shortened version of the ACQ that assesses asthma symptoms (nighttime awakenings, symptoms on waking, activity limitation, shortness of breath, and wheezing) and SABA use while omitting the FEV~1~ measurement from the original ACQ score. Patients were asked to recall their experiences during the previous week and to score each of the questions on a 7-point scale ranging from 0 (totally controlled) to 6 (severely uncontrolled). The overall score was calculated as the mean response to all questions. Mean scores of ≤0.75 indicated well-controlled asthma, scores \>0.75 and \<1.5 indicated partly controlled asthma, and scores ≥1.5 indicated poorly controlled asthma.[@b17-jaa-11-063] Improvement in asthma control is reflected by a decrease in ACQ-6 score. Individual ACQ-6 score changes of ≥0.5 were considered to be clinically meaningful.

Statistical analysis
--------------------

No hypotheses were tested statistically. An estimated sample size of 120 patients was based on the successful enrollment of 100 patients, with adjustment to account for an estimated dropout rate of 17% (20 patients). Summary data were presented in tabular format, and categorical data were summarized by the number and percentage of patients in each category. Continuous data were summarized by descriptive statistics, including N, mean, standard deviation, median, and range. The change from baseline was computed as baseline value subtracted from visit value. If either value was missing, the change from baseline was set to missing.

All analyses were performed by using the full analysis set, except the pharmacokinetic analysis, which used the pharmacokinetic analysis set. The full analysis set included all patients receiving benralizumab, irrespective of their protocol adherence and continued participation in the study. Patients who had at least 1 quantifiable serum benralizumab observation after the first dose were included in the pharmacokinetic analysis data set. An independent data safety monitoring board oversaw the safety and other clinical trial data at regular intervals. All data were analyzed with SAS System version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Patient disposition
-------------------

Patients received treatment at 24 centers in the USA and Canada. Out of 116 patients who received treatment with benralizumab, 7 patients (6%) discontinued treatment. Two of these 7 patients discontinued treatment before receiving their first at-home dose. The reasons for discontinuation of treatment were AE (3 patients \[2.6%\]), patient decision (2 patients \[1.7%\]: 1 before and 1 after the start of the at-home treatment period), severe noncompliance to protocol (1 patient \[0.9%\] had emergency travel preventing administration of the last dose of benralizumab), and development of study-specific discontinuation criteria (1 patient \[0.9%\] had an asthma exacerbation between Weeks 12 and 16). Four patients (3.4%) withdrew from the study. The reasons for withdrawal were patient decision (2 patients \[1.7%\]), AE (1 patient \[0.9%\]), and patient lost to follow up (1 patient \[0.9%\]).

Demographics and baseline clinical characteristics
--------------------------------------------------

Demographics and baseline clinical characteristics were representative of the intended target population of patients with uncontrolled asthma ([Table 1](#t1-jaa-11-063){ref-type="table"}). Patients had a median age of 49 years (range: 18--75 years), and a mean body mass index (BMI) of 32.0 kg/m^2^ (SD: 8.1 kg/m^2^). Most patients were white (81%), and more than half of the patients were female (55%). The median time since asthma diagnosis was 24.4 years (range: 0.9--65.6). Mean prebronchodilator % predicted normal FEV~1~ was 71% (SD: 15%), which was slightly greater than expected for patients with severe asthma. Mean baseline ACQ-6 score was 2.14 (SD: 0.81), which was consistent with expected values for patients who have uncontrolled asthma. The mean number of exacerbations in the past 12 months was 0.6 (SD: 0.8), with the majority of patients (61%) having none. Other key respiratory diseases included allergic rhinitis (83% of patients) and nasal polyposis (16% of patients).

Functionality, reliability, and performance of the APFS
-------------------------------------------------------

Benralizumab was successfully administered to 100% of patients at Weeks 0 (116 patients), 4 (116 patients), and 8 (115 patients), 98% of patients at Week 12 (112/114 patients), and 99% of patients at Week 16 (108/109 patients). Nearly all dispensed APFS were successfully used in the clinic and at home (Week 0: 116/116, 100%; Week 4: 116/117, 99%; Week 8: 115/115, 100%; Week 12: 112/114, 98%; Week 16: 108/109, 99%; [Figure 2](#f2-jaa-11-063){ref-type="fig"}). Of 573 dispensed APFS, only 1 malfunctioned. The malfunction occurred at Week 4 during the period in which benralizumab was administered at the clinical site. The person performing the injection prematurely activated the safety needle guard, rendering the APFS unusable. After evaluation of the manufacturing records and examination of the APFS, it was determined that the malfunction was caused by incorrect assembly of the device by the commercial operator. The APFS was replaced, and benralizumab was successfully administered.

Three APFS were returned as nonfunctional during the period in which benralizumab was administered at home by the patient or caregiver. Two of the 3 devices were nonfunctional because of patient-use error. At Week 12, one patient did not remove the syringe cap on the APFS but did correctly use the replacement device. The second patient did not administer the full dose of benralizumab at Week 16 because the patient sneezed during APFS use. One APFS received a default outcome of nonfunctional because it was not returned.

Benralizumab pharmacokinetics, pharmacodynamics, efficacy, and immunogenicity
-----------------------------------------------------------------------------

Geometric mean serum benralizumab concentrations were 1032 ng/mL at Week 8, 802 ng/mL at Week 20, and 56 ng/mL at Week 28 ([Table 2](#t2-jaa-11-063){ref-type="table"}). The potent anti--IL-5 receptor α properties of benralizumab were evident in that nearly complete depletion of blood eosinophil count occurred by Week 20, and it was maintained to Week 28 ([Figure 3](#f3-jaa-11-063){ref-type="fig"}). By the end of treatment (Week 20), the mean ACQ-6 score decreased compared with the baseline value ([Table 3](#t3-jaa-11-063){ref-type="table"}, [Figure 4](#f4-jaa-11-063){ref-type="fig"}). ACQ-6 score decreased ≥0.5 for 66 patients (57%), representing an improvement in asthma control.

Two patients (2%) were ADA-positive at baseline only, another 2 (2%) were positive at all time points but without boosted ADA titers (defined as \>4-fold increase), and 13 (11%) developed ADAs after the treatment began. Thus, the prevalence and incidence of ADAs were 15% (17 of 116 patients) and 11% (13 of 116), respectively. The presence of neutralizing antibodies did not alter the pharmacodynamics of benralizumab, as demonstrated by comparable eosinophil depletion for ADA-positive and ADA-negative patients ([Figure 3](#f3-jaa-11-063){ref-type="fig"}).

Safety of subcutaneous benralizumab 30 mg administered via an APFS
------------------------------------------------------------------

Benralizumab 30 mg was well tolerated, and the mean duration of exposure of the drug was 110 days (range: 29--124) for all the 116 patients. A total of 19 patients (16%) had 1 asthma exacerbation, 1 patient (1%) had 2 exacerbations, and no patients had an exacerbation that required hospitalization. Of the 116 patients, 77 (66%) had at least 1 AE during the study. Most AEs were mild to moderate. The most common AEs, which were reported for \>5% of patients, were nasopharyngitis, upper respiratory tract infection, headache, and sinusitis ([Table 4](#t4-jaa-11-063){ref-type="table"}). Systemic AEs that the investigator considered to be related to benralizumab administration were nausea (2 patients \[2%\]) and headache, acute sinusitis, arthralgia, dizziness, and fatigue (1 patient \[1%\] each).

Injection-site reactions, which occurred in 5 patients (4%), were considered to be nonserious and mild or moderate, and resolved within 1--15 days. These included injection-site hemorrhage (n=2 \[2%\]), erythema (n=1 \[1%\]), induration (n=1 \[1%\]), and pain (n=1 \[1%\]). No injection-site reaction led to discontinuation of the treatment. No AEs related to device malfunction were reported during the study.

Three patients (3%) discontinued benralizumab treatment because of AEs. By week 8, 1 patient had discontinued treatment and had withdrawn from the study because of acute sinusitis. From Weeks 12--16, 2 patients discontinued treatment because of nausea and dizziness (n=1) and moderate urticaria (n=1). The patient who developed urticaria also withdrew from the study. A total of 7 patients (6%) reported serious AEs, none of which were related to benralizumab treatment.

Discussion
==========

The GREGALE study was conducted to evaluate the functionality, reliability, and performance of an APFS for subcutaneous administration of benralizumab to patients with severe, uncontrolled asthma. Although patients prefer the convenience of administering subcutaneous biologics in an at-home setting, none of the biologics approved for the treatment of severe asthma are approved for at-home use. Based on our literature review, we believe this study is the first to assess the in-clinic and at-home use of an APFS for subcutaneous administration of a biologic for the treatment of severe, uncontrolled asthma. We found that the device performed equally well in the clinic and at home, and that health care providers, patients, and their caregivers could reliably administer subcutaneous benralizumab.

Nearly all dispensed APFS were successfully used in the clinic and at home. Only 1 of 573 dispensed APFS malfunctioned. In this instance, the spring-loaded needle guard was prematurely activated because of an error in APFS assembly. Two APFS were returned as nonfunctional because of user error (1 patient did not remove the needle cap and 1 patient sneezed during injection). One additional APFS was given the default status of nonfunctional because it was not returned and could not be evaluated. Results of this study indicate that health care providers, and the majority of patients and caregivers can be adequately trained to administer subcutaneous benralizumab via an APFS in the clinic and in an at-home setting.

The APFS used in our study is similar to one currently approved for at-home administration of ustekinumab for the treatment of plaque psoriasis.[@b18-jaa-11-063] Both devices contain a pre-filled syringe, which is encapsulated by a needle safety guard. The spring-loaded needle guard is activated by fully depressing the plunger and injecting the entire contents of the syringe. Activation of the needle guard retracts the used needle and prevents needle-stick injury. An additional feature of the APFS used in the GREGALE study is the enlarged finger flanges. These flanges facilitate the user's grip on the device and the application of sufficient force to the plunger to inject a complete dose of benralizumab. There were no reports of needle-stick injuries in our study, and only 1 instance of incomplete injection of benralizumab (the patient sneezed during injection). The device was sufficiently designed to administer benralizumab reliably and be handled safely in the at-home setting.

Pharmacokinetic, pharmacodynamic, and efficacy assessments confirmed that patient and caregiver use of an APFS in an at-home setting was sufficient to achieve benralizumab exposures comparable to those achieved when benralizumab was administered by health care providers at clinical sites. In our study, serum concentrations of benralizumab and improvement in ACQ-6 scores were stable from Week 8 (after the first dose by a health care provider) to Week 20 (after an additional 4 doses, at least 3 of which were administered by the patient/caregiver). Furthermore, the nearly complete depletion of blood eosinophils reported after benralizumab 30 mg injection in other Phase III trials was observed in GREGALE as well.[@b8-jaa-11-063]--[@b10-jaa-11-063],[@b19-jaa-11-063] A concern of respiratory professionals and primary care providers unfamiliar with at-home use of biologics is the potential for nonadherence to treatment when patients self-administer in an unsupervised setting. This concern is alleviated when one considers the fact that rheumatologists, gastroenterologists, dermatologists, and others have been prescribing at-home biologics for many years. The availability of a readily accessible pharmacodynamic biomarker (blood eosinophil count) means that adherence to treatment should be readily detectable.

The safety profile of APFS-administered benralizumab was comparable to that observed for studies in which benralizumab was administered only by health care providers and at clinical sites.[@b8-jaa-11-063]--[@b10-jaa-11-063],[@b19-jaa-11-063] Of particular note was that the incidence of injection-site reactions in GREGALE (4% of patients) was similar to those observed in the 12-week BISE and 28-week ZONDA studies (up to 3% of patients), and no AEs were related to APFS use.[@b9-jaa-11-063],[@b19-jaa-11-063] A longer duration study will be needed to assess long-term efficacy and safety of APFS-administered benralizumab in an at-home setting.

Although the approved dosage of benralizumab is body weight agonistic, the mean baseline BMI for the GREGALE population was high (32 kg/m^2^). A high BMI is not uncommon for patients with severe, uncontrolled asthma and may reflect population-specific factors such as corticosteroid use of high frequency and dosage. A post-hoc analysis of the combined SIROCCO/CALIMA Phase III data set demonstrated that BMI (stratified by ≤35 kg/m^2^ or \>35 kg/m^2^) was not a predictor of benralizumab efficacy.[@b20-jaa-11-063] Thus, we believe the high BMI in the GREGALE study is representative of the target population and was unlikely to influence outcomes.

Conclusion
==========

The use of an APFS at home or in the clinic is a well-tolerated and reliable method for administering subcutaneous benralizumab 30 mg as an add-on treatment for patients with severe, uncontrolled asthma. Self-administration or administration by a caregiver at home would provide a complementary option to administration by health care providers and help optimize patient care.
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![GREGALE study design (**A**) and accessorized pre-filled syringe (**B**).\
**Notes:** \*Patients returned used APFS to the study site. a=enlarged finger flanges; b=spring-loaded needle guard.\
**Abbreviations:** APFS, accessorized pre-filled syringe; EOT, end of treatment; F/U, follow-up; SC, subcutaneous.](jaa-11-063Fig1){#f1-jaa-11-063}

![Percentage of dispensed APFS that were successfully used at the clinical site (**A**) and at home (**B**).\
**Notes:** Successful administration was defined as a completed injection, an answer of "Yes" to all the 5 questions in the questionnaire, and passing results in visual inspection and function tests of the APFS after use.\
**Abbreviation:** APFS, accessorized pre-filled syringe.](jaa-11-063Fig2){#f2-jaa-11-063}

![Median eosinophil counts over time.\
**Notes:** Error bars represent the first and third quartiles.\
**Abbreviation:** ADA, antidrug antibody.](jaa-11-063Fig3){#f3-jaa-11-063}

![Mean (SD) change in ACQ-6 score from baseline.\
**Abbreviations:** ACQ-6, Asthma Control Questionnaire 6; APFS, accessorized pre-filled syringe; EOT, end of treatment.](jaa-11-063Fig4){#f4-jaa-11-063}

###### 

Demographics and baseline clinical characteristics

  Characteristic                                              Benralizumab (N=116)
  ----------------------------------------------------------- ----------------------
  Age (years), median (range)                                 49 (18--75)
  Age group (years), n (%)                                    
   ≥18 to \<50                                                60 (52)
   ≥50 to \<65                                                43 (37)
   ≥65                                                        13 (11)
  Sex, n (%)                                                  
   Male                                                       52 (45)
   Female                                                     64 (55)
  Race, n (%)                                                 
   White                                                      94 (81)
   Black or African-American                                  16 (14)
   Asian                                                      4 (3)
   Other                                                      2 (2)
  Ethnic group, n (%)                                         
   Hispanic or Latino                                         9 (8)
   Not Hispanic or Latino                                     107 (92)
  BMI (kg/m^2^), mean (SD)                                    32.0 (8.1)
  Blood eosinophil count (cells/µL),                          250 (175--430)
  median (IQR)                                                
  FEV~1~ prebronchodilator(L), mean (SD)                      2.311 (0.784)
  FEV~1~ prebronchodilator (% predicted normal), mean (SD)    70.8 (15.4)
  FEV~1~/FVC prebronchodilator (%),mean (SD)                  73 (11)
  FEV~1~ reversibility (%), mean (SD)                         15.9 (14.2)
  Time since asthma diagnosis (years), median (range)         24.4 (0.9--65.6)
  Exacerbations in the previous 12 months, mean (SD), n (%)   0.6 (0.8)
   0                                                          71 (61)
   1                                                          29 (25)
   2                                                          13 (11)
   3                                                          3 (3)
  ACQ-6 score, mean (SD)                                      2.14 (0.81)
  Diagnosis of allergic rhinitis, n (%)                       96 (83)
  Nasal polyps, n (%)                                         18 (16)
  OCS use, n (%)                                              2 (2)

**Abbreviations:** ACQ-6, Asthma Control Questionnaire 6; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; IQR, interquartile range; OCS, oral corticosteroid.

###### 

Serum concentrations of benralizumab

  Pharmacokinetic parameter          Visits                                                                              
  ---------------------------------- ------------------ ------------------ --------------------------------------------- -------------------
  n\<LLOQ                            114                0                  4[a](#tfn2-jaa-11-063){ref-type="table-fn"}   19
  Geometric mean, ng/mL (CV \[%\])   BLQ                1032 (54)          802 (267)                                     56 (500)
  Arithmetic mean, ng/mL (SD)        BLQ                1147 (478)         1205 (658)                                    140 (134)
  Median, ng/mL (range)              BLQ (\<LLOQ--13)   1160 (154--2740)   1140 (\<LLOQ--2820)                           104 (\<LLOQ--579)

**Notes:**

Antidrug antibodies were persistently elevated in all 4 patients, which may have contributed to the lower than expected serum concentrations of benralizumab.

**Abbreviations:** BLQ, below limit of quantification; CV, coefficient of variation; LLOQ, lower limit of quantification (3.86 ng/mL).

###### 

Asthma control status based on ACQ-6 scores at baseline and end of treatment

  Asthma control status                  Benralizumab (N=116)
  -------------------------------------- ----------------------
  Baseline, n (%)                        
   ≤0.75 (well-controlled)               5 (4)
   \>0.75 to \<1.5 (partly controlled)   18 (16)
   ≥1.5 (not well-controlled)            93 (80)
   Missing                               0 (0)
  End of treatment (week 20), n (%)      
   ≤0.75 (well-controlled)               30 (26)
   \>0.75 to \<1.5 (partly controlled)   27 (23)
   ≥1.5 (not well-controlled)            54 (47)
   Missing                               5 (4)

**Abbreviation:** ACQ-6, Asthma Control Questionnaire 6.

###### 

Most common AEs reported (\>5% of patients) during the study period

  Adverse event                                                   Benralizumab 30 mg (N=116)
  --------------------------------------------------------------- ----------------------------
  Patients with ≥1 AE[a](#tfn5-jaa-11-063){ref-type="table-fn"}   77 (66)
   Nasopharyngitis                                                16 (14)
   Upper respiratory tract infection                              13 (11)
   Headache                                                       6 (5)
   Sinusitis                                                      6 (5)

**Notes:**

Patients with \>1 event in the same category were counted only once in that category, and patients with events in \>1 category were counted once in each of those categories.

**Abbreviation:** AE, adverse event.
